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dReaders of the Saudi Heart Journal of will be familiar with the
European System for Cardiac Operative Risk Evaluation
(EuroSCORE) as the world’s most widely used cardiac surgical
risk model (Nashef et al., 1999). Recent papers have cast doubt
on the validity of this model, now more than 10 years old, for
risk assessment in the second decade of the third millennium. It
is worthwhile to pause and reﬂect a little on where we are now
in relation to risk assessment.
1. Why use a risk model?
There are many reasons for using a risk model, but they can be
broadly classiﬁed under two subheadings: assessing the risk for
the patient and evaluating the quality of care provided by the
institution.
Assessing risk
All decisions regarding health care depend on weighing the
beneﬁt against the likely risk, and this is true when a sur-
geon considers offering a treatment to a patient and when
the patient gives informed consent to receiving the treat-
ment. Indeed, when operation is being contemplated on
prognostic grounds alone, in an asymptomatic patient, then
evaluating the risk of surgery becomes of paramount
importance: we must not offer an operation to an asymp-
tomatic patient if surgery carries a greater risk than conser-
vative treatment.
Evaluating care
A risk model offers a standard expected outcome against
which the actual outcome can be measured. If the risk
model says that your predicted mortality should be 5%
for a certain group of patients with a particular risk proﬁle,
and your actual mortality is 1%, then you are doing well.
Dividing actual mortality by your predicted mortality is
termed the ‘‘risk-adjusted mortality ratio’’ or RAMR. This016-7315 ª 2010 King Saud University. All rights reserved. Peer-
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the most useful single measure of the performance of a car-
diac surgical unit.
2. What makes a good risk model?
The validation of a risk model depends on the assessment of
two features: calibration and discrimination. Calibration is
the accuracy of the model for predicting risk in a group of pa-
tients, in other words, if the model says that mortality in a
thousand patients is likely to be 5%, and actual mortality is
5% or close to 5%, then the model is well calibrated. Discrim-
ination refers to the model’s ability to distinguish between low-
risk and high-risk patients. In other words, if most of the
deaths occur in patients that the model correctly identiﬁes as
high-risk, the model has good discrimination, but if most
deaths occur in patients that the model actually identiﬁes as
low-risk, there is poor discrimination. We measure discrimina-
tion using a statistic called the ‘area under the receiver operat-
ing characteristic (ROC) curve’, sometimes also called the c-
statistic or the c-index. If the area under the ROC curve is
0.5, the model does not discriminate at all. Good discrimina-
tion begins at 0.7 and rarely exceeds 0.85. If the area under
the ROC is 1.0, the model is no longer a risk model but a crys-
tal ball which forecasts the future (an impossible task).
It is possible for a risk model to have good calibration but
poor discrimination, and vice versa. Discrimination is more
important than calibration. A model can be recalibrated or
adjusted as practice improves, but if the model is built on
the wrong risk factors, its discrimination cannot be improved.
3. Making electricity in Chicago
EuroSCORE was derived from data on patients operated in
1995 and ﬁrst published in 1999. It is now 10 years old, and
is based on data that are even older. Since the introduction
of EuroSCORE, there has been a quantum improvement in
cardiac surgical survival which occurred in the ﬁrst two to
three years of the new millennium. Evidence from countries
with national databases suggests that mortality in some of
them has approximately halved, despite gradual worsening of
the risk proﬁle of patients. In the United Kingdom, for
32 Editorialexample, mortality has fallen to approximately 55% of logistic
EuroSCORE prediction, giving a UK RAMR of around 0.55.
This phenomenal improvement in cardiac surgical outcomes
appears to have happened in coronary surgery, valve surgery,
combined surgery and other procedures. Yet there has been no
new discovery, drug or technological wizardry to explain such
a large improvement. How did it come about?
In 1955, Landsberger (1958) analysed experiments from
1924 to 1932 at the Hawthorne Works (a Western Elec-
tric plant near Chicago). The company had commissioned a
study to see if its workers would become more productive in
stronger or weaker ambient light. Productivity improved when
lighting was changed in either direction and worsened when
the study was ﬁnished. He concluded that the improvement
was due to the workers being motivated by the interest shown
in them. When other changes were made and their effect sim-
ilarly monitored, such as moving work stations, a similar
improvement in productivity also resulted. The term Haw-
thorne effect was coined to describe the improvement that oc-
curs due to the simple introduction of the monitoring of
outcomes: in other words, when you measure performance, it
improves.
Until the widespread use of EuroSCORE, there was no
established measure of cardiac surgeons’ clinical performance.
EuroSCORE provided the tool for such measurement, and
performance improved. As a result of this improvement, there
is now evidence that the model is no longer appropriately cal-
ibrated, although its discrimination may still be powerful.
EuroSCORE has therefore probably fallen victim to its
own success, in that the heightened awareness of the impor-
tance of clinical outcomes has resulted in improvement which
may have made the model obsolete. Can we conclude from the
above that EuroSCORE is no longer useful for the assessment
of today’s cardiac surgical outcomes? The answer may indeed
be yes, but that requires some new data.
4. The question of calibration
If the improvement in outcomes has occurred across all cardiac
surgery, then recalibration can be made easy. In order to an-
swer the calibration question, we need a large, multi-institu-
tional study. Most recently published studies which were
multi-institutional (Yap et al., 2006; Jin and Grunkemeier,
2006) found overprediction to be the main problem, but there
is an inherent publication bias with institutions which identify
underprediction being less likely, willing or able to publish.
In the meantime, users of EuroSCORE can be assured that
it is still a valuable tool for assessing cardiac surgical risk. As
most studies show, any risk model offers a set standard. Some
units will perform at that standard, some will do better and
some worse. The best estimate for evaluating the risk of mor-
tality for a patient undergoing a particular procedure at a par-
ticular institution is to calculate the logistic EuroSCORE
(Roques et al., 2003) and then to correct it for the performance
of the unit in question, so that the patient should be quoted a
predicted mortality calculated by multiplying the patient’s
EuroSCORE by the hospital’s RAMR as follows:
predicted mortality
¼ patient logistic EuroSCORE hospital mortality
hospital logistic EuroSCOREIn other words, in Hospital X, where the RAMR is 0.7 (actual
mortality = 0.7 of predicted), the patient’s logistic Euro-
SCORE is multiplied by 0.7, reﬂecting the hospital’s perfor-
mance. This becomes crucial if the model is being used to
direct patients towards a treatment such as transcatheter aortic
valve implantation (TAVI) on the basis of risk prediction. If,
for example, it is decided that TAVI should be considered
when the risk of AVR is 20%, it should be 20% at the institu-
tion in question, and not simply if the EuroSCORE is 20%. If
the institution has an RAMR of 1.0, then EuroSCORE can be
used. If the institution has an RAMR of 0.5, then TAVI
should only be offered to patients whose EuroSCORE is 40
or above.
5. The question of discrimination
It is still reasonable to state that EuroSCORE remains power-
ful in discriminating between low-risk and high-risk patients:
to this day the area under the ROC curve in many studies, is
around 0.8 or higher. Despite this, there are probably areas
for improvement. Most notable are that the model ignores
the size of the intervention in many cases, has abrupt cut-off
points for some continuous variables (like pulmonary hyper-
tension, renal function, recency of myocardial infarction and
others). It also ignores hepatic disease, obesity and diabetes.
6. The future: an invitation
The time has therefore come improve the model so that it can
be ﬁt for purpose in cardiac surgery of the current era. We are
now embarking on a major study to update the model and to
reﬁne the risk factors and their assessment so as to improve not
just calibration, but also discrimination.
We could do this in two ways. One way is to use recent data
from the many databases of cardiac surgery that exist through-
out the world. Another is to collect new data. Most databases
are unfortunately not validated and we are not able to verify
their quality. One reason for the success of EuroSCORE is that
it was built on a robust and ‘‘clean’’ database, collected by vol-
unteer centres. We would like to keep that standard, and will
therefore collect new data.
This time, participation will be easier. In 1995, we asked for
around a hundred data points on each patient. The original
risk model has already discarded most of these factors as
unhelpful in risk assessment. Conversely, evidence from studies
suggests that new risk factors should be added and old ones re-
ﬁned. This time, we shall ask for only around 45 data points
and for the majority of patients only about 20 data points will
apply. Most data will be familiar to anyone who already uses
EuroSCORE, with a few additions and reﬁnements. These will
be in the areas of diabetes, obesity, renal and liver function, the
weight of the proposed intervention and one or two other
ﬁelds. Data collection will be online via a dedicated website.
There will be an option to collect paper-based data for later
online transfer for centres requiring that facility. Data will
be conﬁdential, guaranteeing patient, centre and surgeon ano-
nymity to all participants.
It is crucial that the data come from all types of centre, and
not only so-called ‘‘centres of excellence’’. The entire spectrum
of performance must be included and all deaths must be re-
ported so that the risk model reﬂects the reality of cardiac
Editorial 33surgical outcomes. In fact, if only the centres with the best out-
comes participate, the risk model will be harsh on everyone else.
The website is under construction and will be both robust
and user-friendly. Data collection will begin early in 2010.
The exact time period for collecting data is not yet ﬁxed, be-
cause that will depend on the number of centres participating.
The more centres that participate, the quicker the data collec-
tion will be completed. Already more than 200 centres have
committed to the project. We hope that number will increase
very rapidly. If enough centres participate, we may have data
on 40 000 patients in less than 3 weeks. The longest we shall
ask for will be 3 months.
Centres in Saudi Arabia and the Middle East with an inter-
est in participating in this important initiative are invited to
register their interest by following the link from the Euro-
SCORE website (www.euroscore.org). Once interest is regis-
tered, the team will get in touch with additional information
and updates. Any potential participants who have further
queries about the project can contact us by email
(euroscore@papworth.nhs.uk).
We are the same scientiﬁc team that developed the original
EuroSCORE. We remain independent of national and interna-
tional specialist societies, governments and industry. The pro-
ject is currently funded by a scientiﬁc grant from Edwards
Laboratories, by Papworth Hospital, Cambridge and by the
Karolinska University Hospital in Stockholm. Additionalfunding sources are also being sought. Our aim is to produce
the ﬁnest and most practical risk model for cardiac surgeons
and their patients everywhere.
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